About: Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $24.17 (+1.51%)
TNGX NASDAQ Tango Therapeutics Inc
Tango Therapeutics Inc share price
TNGX price activity
Last Price
$24.170
Change (24hr)
0.36 USD (1.51%)
Volume
2.85M
Volume (4w avg)
-
Open
$23.73
Day Range
$23.73 - $24.17
Previous Close
$23.81
Last Trade
12 Oct, 8:00 pm GMT+0
Delayed
12 Oct, 8:00 pm GMT+0
TNGX price performance
Delayed
12 Oct, 8:00 pm GMT+0
TNGX Market Signals